Catch-up growth with normal parathyroid hormone levels in chronic renal failure

Simon Waller1, Sarah Ledermann, Richard Trompeter

  • 1Department of Nephro-Urology, Institute of Child Health and Great Ormond Street Hospital for Children NHS Trust, 30 Guilford Street, London WC1N 1EH, UK. swaller@doctors.net.uk

Insights

Normalizing parathyroid hormone (PTH) levels in children with chronic renal failure (CRF) may promote catch-up growth. This study found improved height standard deviation scores in pediatric CRF patients when PTH levels were managed.

Area of Science:

  • Pediatric Nephrology
  • Endocrinology
  • Growth and Development

Background:

  • The optimal range for parathyroid hormone (PTH) in pediatric chronic renal failure (CRF) is not well-defined.
  • Growth impairment is a common complication in children with CRF.

Purpose of the Study:

  • To assess growth velocity in children with CRF managed towards normal PTH levels.
  • To investigate the relationship between PTH levels and growth in pediatric CRF.

Main Methods:

  • Retrospective review of 99 children with CRF (GFR <41 ml/min per 1.73 m(2)) and at least 2 years of follow-up.
  • Data collected on glomerular filtration rate (GFR), serum calcium, phosphate, PTH, and height standard deviation score (Ht SDS).
  • Analysis of growth changes in relation to various clinical parameters.

Main Results:

  • Children with CRF achieved a mean change in Ht SDS of +0.3, significantly greater than expected (P=0.004).
  • Median PTH levels were at the upper limit of normal, with serum calcium and phosphate near mid-normal ranges.
  • Growth rate was not significantly correlated with age, PTH levels, enteral feeds, or 1-alpha calcidol dosage.

Conclusions:

  • Medical therapy targeting normalized PTH levels can facilitate catch-up growth in pediatric CRF patients.
  • Achieving normal PTH levels appears crucial for improving growth velocity in children with chronic renal failure.

Related Concept Videos

The Parathyroid Glands00:59

The Parathyroid Glands

The two pairs of parathyroid glands embedded within the posterior surface of the thyroid gland are restricted by a dense capsule around them. These glands comprise two distinct cell populations—parathyroid oxyphil and parathyroid principal cells- pivotal in calcium homeostasis.
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by producing...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Skeleton and Calcium Homeostasis01:21

Skeleton and Calcium Homeostasis

Calcium is not only the most abundant mineral in bone but also the most abundant mineral in the human body. Calcium ions are needed for bone mineralization, tooth health, heart rate regulation and strength of contraction, blood coagulation, the contraction of smooth and skeletal muscle cells, and the regulation of nerve impulse conduction. The average calcium level in the blood is about 10 mg/dL. When the body cannot maintain this level, a person will experience hypo or hypercalcemia.
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...